Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperlipidemia is a significant risk factor for cardiovascular disease and mortality post-renal transplantation.
• Statins are commonly used to manage hyperlipidemia, but some renal transplant patients exhibit limited response.
• Atorvastatin, a potent HMG-CoA reductase inhibitor, offers a favorable lipid-lowering profile.

Purpose of the Study:

• To evaluate the efficacy and safety of atorvastatin in hypercholesterolemic renal transplant recipients.
• To assess atorvastatin's effectiveness in patients with a history of poor response to other statins.

Main Methods:

• A cohort of 10 renal transplant recipients with persistent hypercholesterolemia (total cholesterol >240 mg/dl) received atorvastatin 10 mg/day for 3 months.
• All participants had previously used statins for at least 3 months with minimal or no lipid-lowering effect.

Main Results:

• Atorvastatin achieved significant reductions in total cholesterol (311±36.2 to 253±48.8 mg/dl) and LDL cholesterol (184±30.9 to 136±22.9 mg/dl) (P<0.05).
• In patients with elevated baseline triglycerides (>150 mg/dl), atorvastatin markedly reduced triglyceride levels (261±80.3 to 193±53.3 mg/dl) (P<0.05).
• No significant changes were observed in HDL cholesterol, Lp(a), serum creatinine, transaminases, creatinine phosphokinase, or cyclosporin A levels. The drug was well-tolerated without reported myositis or rhabdomyolysis.

Conclusions:

• Short-term atorvastatin therapy is effective in reducing atherogenic lipids in renal transplant patients.
• Atorvastatin presents a viable treatment option for hypercholesterolemia in renal transplant recipients with prior statin non-response.
• The safety profile of atorvastatin in this population appears favorable.